Ong Khaa Hoo, Hsieh Yao-Yu, Lai Hong-Yue, Sun Ding-Ping, Chen Tzu-Ju, Huang Steven Kuan-Hua, Tian Yu-Feng, Chou Chia-Lin, Shiue Yow-Ling, Wu Hung-Chang, Chan Ti-Chun, Tsai Hsin-Hwa, Li Chien-Feng, Kuo Yu-Hsuan
Department of Surgery, Division of Gastroenterology and General Surgery, Chi Mei Medical Center, Tainan 710, Taiwan, R.O.C.
Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan 717, Taiwan, R.O.C.
Oncol Lett. 2023 Oct 30;26(6):533. doi: 10.3892/ol.2023.14120. eCollection 2023 Dec.
Cholangiocarcinoma is a common malignancy with increasing incidence worldwide. Most patients are diagnosed at the advanced stage with poor survival rate. Laminin subunit γ2 (LAMC2) is a heparin binding-associated gene involved in tumorigenesis and has been implicated in the prognosis of various types of cancers. However, it is unclear whether expression of LAMC2 is associated with the clinical outcome of patients with cholangiocarcinoma. In the present study, the role and prognostic value of LAMC2 expression in patients with cholangiocarcinoma was investigated. Clinical information and pathological characteristics were analyzed and the association between LAMC2 expression and clinical characteristics, pathological findings and patient outcomes, including metastasis-free and disease-specific survival, were investigated. Data from 182 patients with cholangiocarcinoma were evaluated. High LAMC2 expression was associated with higher tumor stage (P0.001), large duct type (P=0.024) and poor histological grade (P0.002). Kaplan-Meier analysis showed high LAMC2 expression was associated with lower overall (P=0.003), disease-specific (P0.0025), local recurrence-free (P0.0001) and metastasis-free survival (P0.0001). Moreover, multivariate analysis demonstrated that increased LAMC2 expression was a significant predictive risk factor for overall [hazard ratio (HR) 1.713; P0.034], disease-specific (HR 2.011; P0.039), local recurrence-free (HR 2.721; P0.001) and metastasis-free survival (HR 3.117; P0.001). Gene enrichment analysis using Gene Ontology showed that terms associated with LAMC2 upregulation were 'regulation of platelet-derived growth factor receptor-βsignaling pathway' and 'platelet-derived growth factor receptor-β signaling pathway'. The present study indicated that LAMC2 was upregulated in cholangiocarcinoma tumor tissue and had an inverse association with overall, disease-specific, local recurrence-free and metastasis-free survival in patients with cholangiocarcinoma. These results suggested that LAMC2 may serve as a potential biomarker for cholangiocarcinoma.
胆管癌是一种常见的恶性肿瘤，在全球范围内发病率呈上升趋势。大多数患者在晚期被诊断出来，生存率较低。层粘连蛋白亚基γ2（LAMC2）是一种与肝素结合相关的基因，参与肿瘤发生，并且与多种类型癌症的预后有关。然而，LAMC2的表达是否与胆管癌患者的临床结局相关尚不清楚。在本研究中，调查了LAMC2表达在胆管癌患者中的作用和预后价值。分析了临床信息和病理特征，并研究了LAMC2表达与临床特征、病理结果以及患者结局（包括无转移生存期和疾病特异性生存期）之间的关联。评估了182例胆管癌患者的数据。LAMC2高表达与更高的肿瘤分期（P<0.001）、大胆管类型（P=0.024）和较差的组织学分级（P<0.002）相关。Kaplan-Meier分析显示，LAMC2高表达与更低的总生存期（P=0.003）、疾病特异性生存期（P<0.0025）、无局部复发生存期（P<0.0001）和无转移生存期（P<0.0001）相关。此外，多变量分析表明，LAMC2表达增加是总生存期[风险比（HR）1.713；P<0.034]、疾病特异性生存期（HR 2.011；P<0.039）、无局部复发生存期（HR 2.721；P<0.001）和无转移生存期（HR 3.117；P<0.001）的显著预测风险因素。使用基因本体进行的基因富集分析表明，与LAMC2上调相关的术语是“血小板衍生生长因子受体-β信号通路的调控”和“血小板衍生生长因子受体-β信号通路”。本研究表明，LAMC2在胆管癌肿瘤组织中上调，并且与胆管癌患者的总生存期、疾病特异性生存期、无局部复发生存期和无转移生存期呈负相关。这些结果表明，LAMC2可能作为胆管癌的潜在生物标志物。
